# A Biomarker Is Not an Outcome

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/a-biomarker-is-not-an-outcome

> Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.

## Key points

- hs-CRP −54.6%, insulin resistance −39.1%, adiponectin +47.7% at 15 mg.
- A biomarker panel is not an outcome trial. Cardiology learned that from drugs that improved markers and increased deaths.
- Three of sixteen markers did not move at all; four were NS at lower doses.
- PAI-1 was WEAKEST at the middle dose, which looks like noise, not a dose relationship.
- Sampled only from people who COMPLETED treatment.

Researchers measured sixteen cardiovascular risk markers in SURMOUNT-1 participants at 72 weeks, and most of them improved substantially: inflammation down by more than half at the top dose, insulin resistance down 39%, the protective hormone adiponectin up 48%.[1] It is a striking panel. It is also not evidence that anyone avoided a heart attack, and the difference between those two statements has a body count behind it.

## What was measured

Plasma samples were drawn at baseline, 24 weeks and 72 weeks from 100 randomly selected participants who completed treatment in each SURMOUNT-1 arm (placebo, or tirzepatide at 5, 10 or 15 mg). After samples with insufficient volume were excluded, 392 people remained. Sixteen markers were assayed across four categories: inflammation, metabolic and hepatic stress, endothelial function, and clotting.

*Percent change in geometric means at 72 weeks versus placebo, by dose. NS = not significant. All listed changes adjusted P < 0.05.[1]*

| Marker | 5 mg | 10 mg | 15 mg |
| --- | --- | --- | --- |
| hs-CRP (inflammation) | −36.9% | −46.9% | −54.6% |
| Interleukin-6 | −25.4% | −27.8% | −30.2% |
| Leukocytes | NS | −8.6% | −10.0% |
| HOMA-IR (insulin resistance) | −26.4% | −35.5% | −39.1% |
| Leptin | −44.4% | −59.3% | −61.4% |
| Gamma-glutamyl transferase | −18.6% | −21.6% | −32.7% |
| FGF-21 | −27.4% | −27.6% | −39.9% |
| Adiponectin | **+21.1%** | **+35.1%** | **+47.7%** |
| Free fatty acids | NS | NS | −17.1% |
| sICAM-1 | NS | −9.7% | −11.1% |
| E-selectin | −12.6% | −20.0% | −26.4% |
| PAI-1 antigen | −41.4% | −35.6% | −44.3% |
| Platelets | NS | NS | −6.0% |

Adiponectin rising is the right direction, since it is the one marker here where more is better. Everything else falling is the right direction too. Fibrinogen, tissue plasminogen activator antigen and thrombomodulin showed **no consistent association** and appear in no row above. In other words, three of the sixteen markers did not move.

## The rows that spoil a clean story

Most of the table shows an orderly dose gradient (more drug, more effect), which is the pattern that makes a result believable. Two things break it.

PAI-1 antigen runs −41.4%, −35.6%, −44.3% across the three doses. The *middle* dose performed worst. Nothing about the biology predicts that, and it is the signature of sampling noise in a hundred-person cell rather than a dose relationship.

And four markers (leukocytes, free fatty acids, sICAM-1 and platelets) were not significant at the lower doses. Free fatty acids and platelets reached significance only at 15 mg. A summary saying “tirzepatide improved sixteen cardiovascular biomarkers” would be describing the top dose and quietly generalizing.

## Why a marker is not an event

> **Cardiology learned this expensively, twice.** Torcetrapib raised HDL cholesterol, the marker everyone wanted raised, and its trial was stopped because more people died on it. The antiarrhythmic drugs in the CAST trial suppressed the irregular beats they were designed to suppress, and increased mortality. In both cases the biomarker moved exactly as intended and the patients did worse.

A biomarker is a stand-in for the thing you care about, and the substitution is only as good as the assumption that moving the marker moves the outcome. Sometimes it does. Sometimes the drug moves the marker by a route that has nothing to do with the disease, or does something else harmful at the same time.

> The marker moving is a reason to run the outcome trial. It is not a substitute for having run it.

This does not put tirzepatide in the same position as those examples. Its dose gradients are orderly, the markers point the same way across four unrelated biological systems, and the mechanism is not exotic. All of that raises the odds that the panel reflects something real. It is a stronger prior, not a result.

## The sample is only people who finished

Participants were drawn from those who *completed* treatment. Everyone who stopped, whether because of side effects or anything else, contributed no sample. That selection is invisible in the numbers and it runs in a predictable direction: people who tolerate a drug well are not a random subset of people prescribed it.

So the panel describes what happens in the blood of someone who successfully took tirzepatide for 72 weeks. That is a legitimate question and a narrower one than it appears.

The outcome trial that would settle the question is running. Until it reports, the most that can be said is that tirzepatide moves a wide range of cardiovascular risk markers in the favorable direction, and nobody yet knows what that buys in events. For a case where the events *were* counted, see [how many people to treat to help one](https://glpwatchdog.org/research/how-many-people-to-treat-to-help-one).

## Frequently asked questions

### Does tirzepatide reduce cardiovascular risk?

It substantially improved a wide panel of cardiovascular risk markers at 72 weeks in SURMOUNT-1 participants, including inflammation, insulin resistance, endothelial and clotting measures. Whether that translates into fewer heart attacks and strokes requires an outcome trial, which this was not.

### Why isn't an improved biomarker enough?

Because drugs have improved their target markers and harmed patients. Torcetrapib raised HDL cholesterol and increased deaths; the CAST antiarrhythmics suppressed the irregular beats they targeted and increased mortality. A marker is a stand-in, and the substitution can fail.

### Which markers changed most?

At 15 mg, hs-CRP fell 54.6%, leptin 61.4%, insulin resistance 39.1%, and adiponectin, where an increase is favorable, rose 47.7%.

### Did everything improve?

No. Fibrinogen, tissue plasminogen activator antigen and thrombomodulin showed no consistent association. Leukocytes, free fatty acids, sICAM-1 and platelets were not significant at the lower doses.

### Who was sampled?

One hundred randomly selected participants from each arm who completed treatment, leaving 392 after low-volume samples were excluded. Anyone who stopped the drug is absent, so this describes people who tolerated it.

## References

1. Sattar N, Linetzky B, Ruotolo G, et al. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. Journal of the American College of Cardiology. 2026. PMID: 42233927. https://pubmed.ncbi.nlm.nih.gov/42233927/

---

Cite as: GLP Watchdog, Nora Bissett, "A Biomarker Is Not an Outcome", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/a-biomarker-is-not-an-outcome

Canonical HTML page: https://glpwatchdog.org/research/a-biomarker-is-not-an-outcome

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
